EP0580752A1 - Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain - Google Patents

Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain

Info

Publication number
EP0580752A1
EP0580752A1 EP92910967A EP92910967A EP0580752A1 EP 0580752 A1 EP0580752 A1 EP 0580752A1 EP 92910967 A EP92910967 A EP 92910967A EP 92910967 A EP92910967 A EP 92910967A EP 0580752 A1 EP0580752 A1 EP 0580752A1
Authority
EP
European Patent Office
Prior art keywords
igfbp
hbd
igf
bone
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92910967A
Other languages
German (de)
English (en)
Other versions
EP0580752A4 (en
Inventor
Mannheim Gmbh Boehringer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of EP0580752A1 publication Critical patent/EP0580752A1/fr
Publication of EP0580752A4 publication Critical patent/EP0580752A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions purifiées et isolées d'une protéine de liaison pour facteurs de croissance analogues à l'insuline (IGFs) I et II. La protéine de liaison, connue sous l'appellation de protéine de liaison d'IGF dérivée d'os humain (hBD-IGFBP), potentialise les effets prolifératifs de IGF-II sur des cellules osseuses. L'invention concerne également des méthodes de diagnostic pour hBD-IGFBP, ainsi que des compositions pharmaceutiques et des procédés de traitement de troubles osseux, de cicatrisation de lésions, de réparation de la peau, et de modulation de l'activité des IGF dans les os.
EP9292910967A 1991-04-19 1992-04-15 Human bone derived insulin like growth factor binding protein Withdrawn EP0580752A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68835391A 1991-04-19 1991-04-19
US688353 1991-04-19

Publications (2)

Publication Number Publication Date
EP0580752A1 true EP0580752A1 (fr) 1994-02-02
EP0580752A4 EP0580752A4 (en) 1994-08-24

Family

ID=24764088

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9292910967A Withdrawn EP0580752A4 (en) 1991-04-19 1992-04-15 Human bone derived insulin like growth factor binding protein

Country Status (11)

Country Link
EP (1) EP0580752A4 (fr)
JP (1) JP2527896B2 (fr)
KR (1) KR0129864B1 (fr)
AU (1) AU658187B2 (fr)
CA (1) CA2107475A1 (fr)
CZ (1) CZ283601B6 (fr)
FI (1) FI934588A0 (fr)
HU (1) HUT70297A (fr)
NO (1) NO933742L (fr)
RU (1) RU2114120C1 (fr)
WO (1) WO1992018154A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233155T2 (de) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
EP0800530A4 (fr) * 1994-07-20 1998-12-02 Celtrix Pharma Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
US20190018025A1 (en) * 2015-12-31 2019-01-17 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
US10212614B2 (en) * 2015-12-31 2019-02-19 Facebook, Inc. Igniting network nodes in a multi-hop wireless network

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7907958A (nl) * 1979-10-30 1981-06-01 Wijn Adriaan Jacques De Kar of onderstel voorzien van opklapbare wielen.
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
ATE112684T1 (de) * 1987-04-28 1994-10-15 Boehringer Mannheim Gmbh Verwendung von igf-ii zur behandlung von knochenkrankheiten.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 176, no. 1 , 15 April 1991 , DULUTH, MINNESOTA US pages 213 - 218 ANDRESS, D. L. ET AL. 'A novel human insulin-like growth factor binding protein secreted by osteoblast-like cells' *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 176, no. 2 , 30 April 1991 , DULUTH, MINNESOTA US pages 756 - 763 BAUTISTA, C. M. ET AL. 'Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: A potential canditate for fixing IGF-II in human bone' *
See also references of WO9218154A1 *

Also Published As

Publication number Publication date
JP2527896B2 (ja) 1996-08-28
NO933742L (no) 1993-10-18
CA2107475A1 (fr) 1992-10-20
JPH06501270A (ja) 1994-02-10
WO1992018154A1 (fr) 1992-10-29
AU1784492A (en) 1992-11-17
FI934588A (fi) 1993-10-18
KR0129864B1 (en) 1998-04-09
AU658187B2 (en) 1995-04-06
CZ219093A3 (en) 1994-12-15
EP0580752A4 (en) 1994-08-24
CZ283601B6 (cs) 1998-05-13
FI934588A0 (fi) 1993-10-18
HU9302942D0 (en) 1994-01-28
HUT70297A (en) 1995-09-28
RU2114120C1 (ru) 1998-06-27

Similar Documents

Publication Publication Date Title
US5561046A (en) Methods for the detection of acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
Luetteke et al. Characterization of high molecular weight transforming growth factor. alpha. produced by rat hepatocellular carcinoma cells
AU623447B2 (en) Binding protein for insulin-like growth factors
JP2648951B2 (ja) 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
JP3178714B2 (ja) インスリン様成長因子（ｉｇｆ）結合蛋白複合体の酸不安定サブユニット（ａｌｓ）
EP0546110B1 (fr) Nouvelle proteine de liaison de facteur de croissance analogue a l'insuline igfbp-5
Perkel et al. An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP
AU658187B2 (en) Human bone derived insulin like growth factor binding protein
WO1992003470A1 (fr) Matiere genetique codant la ifgbp-5
US5453489A (en) Polypeptide fragments of fibronectin which can modulate extracellular matrix assembly
US5919902A (en) Leptin bound to inter-alphatrypsin inhibitor and uses thereof
JPH11506337A (ja) 骨刺激因子
WO1999049894A1 (fr) Antagonistes du gene 6 specifique de l'arret de croissance, et leur utilisation contre des troubles insulinoresistants
Ogata Demonstration of pancreatic secretory trypsin inhibitor in serum-free culture medium conditioned by the human pancreatic carcinoma cell line CAPAN-1.
WO1994025057A1 (fr) Antagonistes de la liaison du kgf derives du recepteur de kgf
US5693754A (en) Inhibitory binding protein for insulin-like growth factors
US7125961B2 (en) Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
US6329500B1 (en) Transforming growth factor-β binding site
AU638935B2 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf)binding protein complex
CA2191321A1 (fr) Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse
JP3025002B2 (ja) Ｄｎａ、ポリペプチド、抗体、およびそれらの用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C07K 15/06

A4 Supplementary search report drawn up and despatched

Effective date: 19940705

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19980505

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990914